[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc completed a tranche of its share buyback programme, acquiring 5,214,540 ordinary shares (₣0.01 each) on 17 September 2025. The company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 14,573,545 are held in treasury, leaving 8,937,780,103 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the company's investor website.

Insights

Financial Analyst

TL;DR: Small, routine tranche of a buyback; updates share count and treasury holdings but no earnings or cash detail disclosed.

The announcement documents the purchase of 5,214,540 shares under the second tranche of the previously announced buyback. Management will hold these as treasury shares and provides the updated counts for registered capital, treasury holdings and voting shares, enabling shareholders to assess disclosure thresholds under FCA rules. The filing does not disclose purchase funding, total programme size remaining, or financial impact on cash or EPS.

Corporate Governance Expert

TL;DR: Corporate action is procedural and compliant, supplying required post-trade share totals for regulatory reporting.

The disclosure complies with Market Abuse Regulation requirements by providing a trade breakdown link and updated share capital figures. By holding shares in treasury, Haleon has preserved flexibility for future use. The filing supplies the precise voting share count investors need for threshold notifications but contains no commentary on board authorization limits or timing for further tranches.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐                  

EXHIBIT INDEX

Exhibit Number	Description
99.1	18 September 2025- “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

18 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 5,214,540 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	17 September 2025	17 September 2025	17 September 2025
Number of Shares purchased:	3,315,000	1,899,540	-
Highest price paid per Share (p):	343.9000	343.0000	-
Lowest price paid per Share (p):	340.8000	340.8000	-
Volume weighted average price paid per Share (p):	342.6323	342.5237	-

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 14,573,545 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,937,780,103 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/7745Z_1-2025-9-17.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 18, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary